| Molecular target | Indications | Administration route | Recommended dose and frequency | Half-life |
---|---|---|---|---|---|
Erenumab | CGRP receptor | Preventive treatment | subcutaneous | 70 or 140Â mg, monthly | 28Â days |
Fremanezumab | CGRP | Preventive treatment | subcutaneous | 225Â mg (monthly), 675Â mg (quarterly) | 31Â days |
Galcanezumab | CGRP | Preventive treatment | subcutaneous | 120Â mg (first dose 240Â mg), monthly | 27Â days |
Eptinezumab | CGRP | Preventive treatment | intravenous | 100 or 300Â mg, quarterly | 27Â days |